IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline.
Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to
five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA Pharmaceutical Solutions